Patrick R Benusiglio

List of Publications by Year
in descending order

42	2,383	361413	265206
papers	citations	20 h-index	42 g-index

44	44	44	3906
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. Leukemia, 2022, 36, 126-137.	7.2	10
2	Preimplantation genetic testing in patients with genetic susceptibility to cancer. Familial Cancer, 2022, , 1.	1.9	1
3	Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?. Journal of Clinical Oncology, 2022, , JCO2200488.	1.6	1
4	International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study. Gastric Cancer, 2022, 25, 1094-1104.	5.3	7
5	Response to systemic therapy in fumarate hydrataseâ€“deficient renal cell carcinoma. European Journal of Cancer, 2021, 151, 106-114.	2.8	18
6	Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. American Journal of Human Genetics, 2021, 108, 1907-1923.	6.2	14
7	Cancer predisposition and germline CTNNA1 variants. European Journal of Medical Genetics, 2021, 64, 104316.	1.3	21
8	Lung cancer is also a hereditary disease. European Respiratory Review, 2021, 30, 210045.	7.1	39
9	Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic. European Journal of Medical Genetics, 2020, 63, 104098.	1.3	7
10	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	10.7	237
11	Overcoming the challenges associated with universal screening for Lynch syndrome in colorectal and endometrial cancer. Genetics in Medicine, 2020, 22, 1422-1423.	2.4	3
12	Germline Variants in Highly Selected Patients With Prostate Cancer. JAMA Oncology, 2019, 5, 1367.	7.1	1
13	Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast) Tj ETQq1 1 0.784314 rgBT /Overlock 25, 16-19.	1.0	7
14	Clinical implications of CTNNA1 germline mutations in asymptomatic carriers. Gastric Cancer, 2019, 22, 899-903.	5.3	27
15	Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Modern Pathology, 2018, 31, 974-983.	5.5	65
16	Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted. Gynecologic Oncology Reports, 2018, 26, 69-70.	0.6	0
17	CDH1 germline mutations: different syndromes, same management?. Genetics in Medicine, 2017, 19, 965-966.	2.4	6
18	GermlineCDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma. Journal of Medical Genetics, 2017, 54, 607-612.	3.2	19

#	Article	IF	Citations
19	Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French <scp>FH</scp> mutation carriers. Clinical Genetics, 2017, 92, 606-615.	2.0	103
20	Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum. JAMA Oncology, 2017, 3, 1736.	7.1	24
21	Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling. Familial Cancer, 2017, 16, 51-56.	1.9	15
22	Deficit of Risk-Reducing Salpingo-Oophorectomies in BRCA1/2 Mutation Carriers After Telephone Genetic Counseling. Journal of Clinical Oncology, 2017, 35, 1255-1255.	1.6	3
23	Whole-Body MRI Screening in Children With Li-Fraumeni and Other Cancer Predisposition Syndromes.. American Journal of Roentgenology, 2016, 206, W52-W52.	2.2	5
24	The Birt-Hogg-DugÃ© cancer predisposition syndrome: Current challenges. Intractable and Rare Diseases Research, 2015, 4, 162-163.	0.9	6
25	Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. Journal of Clinical Oncology, 2015, 33, 2345-2352.	1.6	525
26	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
27	Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with aCDH1germline mutation. Journal of Medical Genetics, 2015, 52, 563-565.	3.2	22
28	A germline mutation inPBRM1predisposes to renal cell carcinoma. Journal of Medical Genetics, 2015, 52, 426-430.	3.2	38
29	Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Research, 2015, 17, 37.	5.0	126
30	Renal cell tumour characteristics in patients with the Birt-Hogg-DubÃ© cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet Journal of Rare Diseases, 2014, 9, 163.	2.7	78
31	Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis. Cancer Research, 2014, 74, 6554-6564.	0.9	32
32	Case Report: Expanding the tumour spectrum associated with the Birt-Hogg-DubÃ© cancer susceptibility syndrome. F1000Research, 2014, 3, 159.	1.6	7
33	CDH1germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. Journal of Medical Genetics, 2013, 50, 486-489.	3.2	131
34	Cleft lip, cleft palate, hereditary diffuse gastric cancer and germline mutations in CDH1. International Journal of Cancer, 2013, 132, 2470-2470.	5.1	29
35	Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report. Journal of Medical Case Reports, 2011, 5, 110.	0.8	3
36	Focus on ERBB2. Pharmacogenomics, 2008, 9, 825-828.	1.3	4

#	Article	IF	Citations
37	Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis, 2008, 29, 333-341.	2.8	68
38	Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Research, 2007, 9, R27.	5.0	94
39	HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. British Journal of Cancer, 2006, 95, 1689-1695.	6.4	35
40	Common variation in EMSYand risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs. BMC Cancer, 2005, 5, 81.	2.6	14
41	Reply: a bias in genotyping of the ERBB2 (HER2) Ile655Val variant. Carcinogenesis, 2005, 26, 2213-2213.	2.8	1
42	Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a caseâ€“control study. Breast Cancer Research, 2005, 7, R204-9.	5.0	55